Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3‐TACC3 Fusion and Recurrent Glioblastoma

We describe a case of recurrent glioblastoma treated with anlotinib in this report. The patient was administered anlotinib 12 mg p.o. once every day (days 1–14, with a 21‐day cycle) (anlotinib clinical study NCT04004975) and oral temozolomide chemotherapy 100 mg/m(2) (days 1–7, days 15–21, 28‐day cy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Wang, Yong, Liang, Dandan, Chen, Jimin, Chen, Huan, Fan, Rui, Gao, Ye, Gao, Yongsheng, Tao, Rongjie, Zhang, Henghui
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Precision Medicine Clinic: Molecular Tumor Board
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930428/
https://ncbi.nlm.nih.gov/pubmed/32949176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13530
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller